DIM as a Treatment for Thyroid Disease

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər

Giriş / Qeydiyyatdan keçin

Bağlantı panoya saxlanılır

StatusXitam verilib

Sponsorlar

The New York Eye & Ear Infirmary

KLINIK SINAQ: NCT01846364

BioSeek: nct01846364

Açar sözlər

Mücərrəd

Diindolylmethane (DIM), a dietary supplement, found naturally in cruciferous vegetables (such as cabbage, cauliflower, broccoli, & Brussels sprouts) has been studied extensively in recent years for its anti-cancer effects. DIM has been shown to exert control over cancer cell growth in breast, uterine, cervical, ovarian, and colon cancer.

To date no human study has been published regarding the bioavailability of DIM in thyroid tissue or its effects in proliferative thyroid disease. Our previous study attempted to elucidate DIM's promotion of anti-proliferative estrogen metabolites in proliferative thyroid disease and ascertain its uptake in thyroid tissue. DIM has been shown to concentrate in the thyroid gland. Furthermore, thyroid volumes have been seen to decrease subjectively.

This study would continue our attempt to elucidate DIM's promotion of anti-proliferative estrogen metabolites in proliferative thyroid disease.

Tarixlər

Son Doğrulandı:	03/31/2013
İlk təqdim:	04/29/2013
Təxmini qeydiyyat təqdim edildi:	04/29/2013
İlk Göndərmə:	05/02/2013
Son Yeniləmə Göndərildi:	04/29/2013
Son Yeniləmə Göndərildi:	05/02/2013
Həqiqi Təhsilin Başlama Tarixi:	10/31/2006
Təxmini İlkin Tamamlanma Tarixi:	07/31/2011
Təxmini İşin Tamamlanma Tarixi:	08/31/2011

Vəziyyət və ya xəstəlik

Proliferative Thyroid Disease

Müdaxilə / müalicə

Dietary Supplement: A

Faza

Qol Qrupları

Qol	Müdaxilə / müalicə
Experimental: A Subjects with proliferative thyroid disease	Dietary Supplement: A 300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar	18 Years Üçün 18 Years
Təhsilə Uyğun Cinslər	All
Sağlam Könüllüləri qəbul edir	Bəli
Kriteriyalar	Inclusion Criteria: - Adults diagnosed with abnormalities of the thyroid gland suspicious for benign adenoma, or goiterous changes. Exclusion Criteria: - Patients who are pregnant, attempting to conceive, or lactating will be excluded due to possible deleterious effects of treatment on fetus/infant. Patients taking oral contraceptives, estrogen therapy, tamoxifin or those with a history of breast cancer will be excluded. Patients with liver disease and those taking statins for hypercholesterolemia will also be excluded to decrease the potential for possible liver toxicity. Any patient with elevated liver enzymes on pretreatment blood screening will be excluded from study participation. Patients with serious systemic diseases such as renal failure, diabetes, blood dyscrasia, coagulopathy, and non-optimized cardiopulmonary disease will be excluded due to the possibility of confounding blood tests screening for toxicity.

Nəticə

İlkin nəticə tədbirləri

1. Evidence of objective and quantifiable changes in thyroid size as a resalt of the oral administration of DIM, confirmed by pre- and post- DIM treatment ultrasounds [after 30 days of DIM consumption and 2 and 4 weeks after DIM consumption stopped]

İkincili Nəticə Tədbirləri

1. Evidence of DIM's effect on estrogen metabolites, confirmed by plasma and urine analysis [after 30 days of DIM consumption]

DIM as a Treatment for Thyroid Disease

Açar sözlər

xərçəng xəstəliyi

diindolylmethane

kələm

bostan kələmi

antikanser